Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4
Adolescent
Adult
Antineoplastic Agents
/ pharmacokinetics
Asparaginase
/ blood
Asparagine
/ cerebrospinal fluid
Biomarkers, Tumor
/ analysis
Child
Child, Preschool
Female
Follow-Up Studies
Humans
Infant
Male
Polyethylene Glycols
/ therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ blood
Prognosis
Tissue Distribution
Young Adult
Lymphoid Leukemia
asparaginase
asparagine depletion
pharmacodynamics
pharmacokinetics
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
pubmed:
11
1
2019
medline:
29
7
2020
entrez:
11
1
2019
Statut:
ppublish
Résumé
The efficacy of asparaginase in acute lymphoblastic leukemia (ALL) is dependent on depletion of asparagine, an essential amino acid for ALL cells. The target level of plasma asparaginase activity to achieve asparagine depletion has been between 0.05 and 0.4 IU/mL. COG AALL07P4 examined the asparaginase activity and plasma and CSF asparagine concentration of pegaspargase when given intravenously in the treatment of NCI high risk ALL. Matched plasma asparaginase/asparagine levels of the clearance of 54 doses of pegaspargase given in induction or consolidation demonstrated that all patients who had a plasma asparaginase level >0.02 IU/mL had undetectable plasma asparagine. No difference was observed in CSF asparagine levels associated with matched plasma asparaginase levels of 0.02-0.049 versus 0.05-0.22 IU/mL (
Identifiants
pubmed: 30626253
doi: 10.1080/10428194.2018.1542146
pmc: PMC6594900
mid: NIHMS1520186
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
Polyethylene Glycols
3WJQ0SDW1A
Asparagine
7006-34-0
pegaspargase
7D96IR0PPM
Asparaginase
EC 3.5.1.1
Banques de données
ClinicalTrials.gov
['NCT00671034']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1740-1748Subventions
Organisme : NCI NIH HHS
ID : U10 CA098413
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA098543
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180886
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180899
Pays : United States
Références
Br J Haematol. 1999 Feb;104(2):313-20
pubmed: 10050714
Ann Oncol. 2000 Feb;11(2):189-93
pubmed: 10761754
Br J Haematol. 2000 Aug;110(2):379-84
pubmed: 10971395
Br J Clin Pharmacol. 2001 Oct;52(4):433-7
pubmed: 11678787
Br J Haematol. 2001 Dec;115(4):983-90
pubmed: 11843837
Blood. 2002 Mar 15;99(6):1986-94
pubmed: 11877270
Cancer Chemother Pharmacol. 2002 Aug;50(2):117-20
pubmed: 12172975
J Exp Med. 1963 Jul;118:99-120
pubmed: 14015821
J Exp Med. 1963 Jul;118:121-48
pubmed: 14015822
Clin Pharmacokinet. 2005;44(4):367-93
pubmed: 15828851
Blood. 2007 Apr 1;109(7):2744-50
pubmed: 17132721
Cancer Res. 1991 Dec 15;51(24):6568-73
pubmed: 1742729
Br J Haematol. 2010 Jan;148(1):119-25
pubmed: 19821822
Blood. 2013 Jul 25;122(4):507-14
pubmed: 23741010
Ther Drug Monit. 2014 Aug;36(4):549-52
pubmed: 24342897
J Clin Oncol. 2014 Dec 1;32(34):3874-82
pubmed: 25348002
Pediatr Blood Cancer. 2015 Jun;62(6):1102-5
pubmed: 25393506
Leuk Lymphoma. 2015;56(8):2273-80
pubmed: 25586605
N Engl J Med. 2015 Oct 15;373(16):1541-52
pubmed: 26465987
Lancet Oncol. 2015 Dec;16(16):1677-90
pubmed: 26549586
Cancer Res. 1981 Nov;41(11 Pt 1):4554-8
pubmed: 6895481
J Clin Oncol. 1996 Jan;14(1):18-24
pubmed: 8558195
Eur J Cancer. 1996 Aug;32A(9):1544-50
pubmed: 8911116
Br J Haematol. 1997 Mar;96(4):675-81
pubmed: 9074406